Overview of clinical experience with ciprofloxacin.
Ciprofloxacin is a new 4-quinolone antibacterial agent with an extended antibacterial spectrum, enhanced potency and the ability to produce therapeutic serum, tissue and urine concentrations after oral administration. Unlike earlier 4-quinolones, it is active against gram-positive cocci and opportunistic organisms such as Pseudomonas aeruginosa. This overview demonstrates that the oral formulation has been shown to be clinically effective in a broad range of urinary and respiratory infections, gonorrhoea, gastro-intestinal infections including typhoid fever, surgical infections, skin and soft tissue sepsis and in a variety of infections caused by Pseudomonas aeruginosa, notably cystic fibrosis. Adverse reactions are infrequent and in almost every case have proved mild and transient. Ciprofloxacin has great potential for the oral therapy of infections which have traditionally required parenteral chemotherapy.
D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002939:Ciprofloxacin; D004751:Enteritis / Q000188:drug therapy; D004755:Enterobacteriaceae / Q000187:drug effects; D006069:Gonorrhea / Q000188:drug therapy; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011804:Quinolines / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects; D059005:Topoisomerase II Inhibitors; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D011804:Quinolines; D059005:Topoisomerase II Inhibitors; D002939:Ciprofloxacin